ReviewFrontiers in allergy2025
Gut-lung axis in asthma and obesity: role of the gut microbiome.
Review in Frontiers in allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness of Metabolic and Bariatric Surgery for Patients with Obesity and Asthma: A Systematic Review and Meta-Analysis.Obesity surgery · 2026Pooled it
- Probiotics in asthma: immunoregulatory mechanisms and emerging opportunities for respiratory delivery-a narrative review.Translational pediatrics · 2026Review
- MaternalBiomedicines · 2026Article
- Metabolic Reprogramming and ILC2 Plasticity in Obesity-related Asthma.Clinical reviews in allergy & immunology · 2026Review
- Butyrate remodels the immune-epigenetic-gut-lung axis: Emerging mechanisms and therapeutic perspectives in asthma.Seminars in immunopathology · 2026Review
- [Pathological roles of lipid metabolism disorders in asthma and related intervention strategies].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Review
- The Inflammation-Metabolism Axis in Preserved Ratio Impaired Spirometry: Pathogenic Mechanisms and Translational Implications.Journal of inflammation research · 2026Review
- Intestinal neutral ceramidase exacerbates MASH pathogenesis.eGastroenterology · 2026Article
- Non-type 2 airway inflammation in severe asthma: from bench to bedside.Frontiers in immunology · 2026Review
- Microbiota-Driven Immune Dysregulation Along the Gut-Lung-Vascular Axis in Asthma and Atherosclerosis.Biomedicines · 2025Review
- Article
- Clinical Treatment and Clinical Application Research Progress of Psoriasis and Intestinal Microbiota Dysbiosis.Clinical, cosmetic and investigational dermatology · 2025Review
- The gut-lung axis in asthma: microbiota-driven mechanisms and therapeutic perspectives.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a heterogeneous disease whose severity is exacerbated by obesity. Despite its clinical importance, targeted therapies for asthma in obese patients remain limited. Recent evidence highlights the gut microbiome as a crucial factor linking metabolic and immune pathways involved in both asthma and obesity. This review explores the complex interplay between the gut microbiome, immune responses, and the gut-lung axis, emphasizing how microbial composition, diversity, and metabolites, such as short-chain fatty acids (SCFAs), influence airway hyperresponsiveness (AHR) and airway inflammation. Obesity alters the gut microbiome, contributing to systemic inflammation and metabolic dysfunction. Furthermore, asthma phenotypes related to obesity are associated with specific gut microbial profiles, suggesting a causal relationship. Animal studies have demonstrated that manipulation of the gut microbiome through diet, antibiotics, or microbial transplantation can alter asthma outcomes, particularly in obesity models. Given these findings, targeting the gut microbiome might be a promising therapeutic strategy for asthma in obese individuals. Potential interventions include probiotics, prebiotics and antibiotics, all of which have shown varying degrees of effectiveness in modulating airway inflammation and reducing asthma severity. This review provides a comprehensive overview of current knowledge and proposes future directions for microbiome-targeted therapies in managing severe asthma associated with obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.